Disease · MONDO_0016264
autoimmune hepatitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. autoimmune hepatitis. Diseases, record MONDO_0016264. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016264
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs25
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INEBILIZUMAB | CHEMBL2109334 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PAEONIFLORIN | CHEMBL4303209 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PHOSPHATIDYLCHOLINE | CHEMBL503481 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SILYMARIN | CHEMBL4630684 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| AZATHIOPRINE | CHEMBL1542 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IANALUMAB | CHEMBL4594357 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 25
See all 25 drugsTargets18
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CD19 | B-lymphocyte antigen CD19 | 1 | B-lymphocyte antigen CD19 binding agent | Phase 3 | https://conductscience.org/library/genes/930 | Drugs and targets |
| CD2 | T-cell surface antigen CD2 | 1 | T-cell surface antigen CD2 inhibitor | Phase 1 | https://conductscience.org/library/genes/914 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 1 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 1 | https://conductscience.org/library/genes/942 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| EPOR | Erythropoietin receptor | 1 | Erythropoietin receptor agonist | Early phase 1 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/3560 | Drugs and targets |
1 to 10 of 18
See all 18 targetsTrials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02239562 | sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS | Phase 1 | 36 | 2019-11-20 | Autoimmune Hepatitis | PREIMPLANTATION FACTOR | Its record names the disease | ClinicalTrials.gov |
| NCT05569759 | A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) | Phase 2 | 24 | 2026-01-13 | Autoimmune Hepatitis | ZETOMIPZOMIB | Its record names the disease | ClinicalTrials.gov |
| NCT00608894 | LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis | Phase 2 | 13 | 2020-03-06 | Autoimmune Hepatitis | AZATHIOPRINE, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT04790916 | Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH) | Phase 2 | 2 | 2023-09-18 | Autoimmune Hepatitis, Autoimmune Chronic Hepatitis | MELREDABLEUKIN ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT05812612 | UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease | 2,000 | COVID-19 Infection | URSODIOL | Its record names the disease | ClinicalTrials.gov | ||
| NCT04028869 | Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease | 400 | Autoimmune Liver Disease | GLYCYRRHIZIN | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT00838214 | Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis | Phase 2/3 | 208 | Autoimmune Hepatitis | BUDESONIDE, PREDNISONE | Its record names the disease | ClinicalTrials.gov | |
| NCT07598825 | A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Phase 3 | 180 | Autoimmune Hepatitis, AIH | INEBILIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06650124 | Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF | Phase 2/3 | 108 | Autoimmune Hepatitis | AZATHIOPRINE, MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov | |
| NCT01988506 | Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases | Phase 2 | 81 | Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis, Behcet's Disease, Wegener's Granulomatosis, Takayasu's Disease, Crohn's Disease, Ulcerative Colitis, Autoimmune Hepatitis, Sclerosing Cholangitis, Gougerot-sjögren, Idiopathic Thrombocytopenic Purpura, Systemic Sclerosis | ALDESLEUKIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Double-blind Treatment Period: Zetomipzomib + Standard-of-care (Glucocorticoids) vs Double-blind Treatment Period: Placebo + Standard-of-care (Glucocorticoids): Disease Flare After CR | 0 of 16 | 0 of 8 | 24 | NCT05569759 | Trial comparisons |
| Double-blind Treatment Period: Zetomipzomib + Standard-of-care (Glucocorticoids) vs Double-blind Treatment Period: Placebo + Standard-of-care (Glucocorticoids): Treatment Failures | 2 of 16 | 1 of 8 | 24 | NCT05569759 | Trial comparisons |
| LCP-Tacro vs Azathioprine: Biochemical Remission of (AIH) at Month 6. | 3 of 7 | 4 of 6 | 13 | NCT00608894 | Trial comparisons |
| LCP-Tacro vs Azathioprine: deaths from any cause | 0 of 7 | 0 of 6 | 13 | NCT00608894 | Trial comparisons |
| LCP-Tacro vs Azathioprine: serious adverse events | 0 of 7 | 0 of 6 | 13 | NCT00608894 | Trial comparisons |
| LCP-Tacro vs Azathioprine: Biochemical Remission by Month 3. | 2 of 7 | 4 of 4 | 11 | NCT00608894 | Trial comparisons |
Open-label Extension: Zetomipzomib + standard-of Care (Glucocorticoids) (Zetomipzomib in DBTP) vs Open-label Extension: Zetomipzomib + standard-of Care (Glucocorticoids) (Placebo in DBTP): Proportion of Participants Experiencing a Disease Flare Among the Participants Who Achieved a CR During the Double-blind Treatment Period | 0 of 5 | 0 of 2 | 7 | NCT05569759 | Trial comparisons |
Papers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016264
GET https://conductscience.org/api/diseases/v1/MONDO_0016264/drugs?page=2